Press Releases
Mike Romanos Appointed as CEO of Crescendo Biologics
5 January 2011
Crescendo Biologics Limited (Crescendo) today announces the appointment of Mike Romanos as Chief Executive Officer. Dr Romanos has been Chief Scientific Officer of the company since May 2009 and has led the formation of the company and the development of its proprietary antibody fragment technologies. Read more
Crescendo Biologics Announces First ‘Triple Knockout’ Mouse
29 September 2010
Crescendo Biologics Limited (Crescendo) today announces it has established a colony of engineered mice completely devoid of endogenous antibody polypeptides. The proprietary ‘triple knockout’ mice are believed to be unique and have the immunoglobulin heavy chain (IgH), kappa light chain and lambda light chain loci all functionally silenced by large-scale genomic deletion. Read more
Clive Dix Appointed as Chairman of Crescendo Biologics
8 January 2010
Crescendo Biologics (“Crescendo”) today announces the appointment of Clive Dix as Chairman. Dr Dix will work closely with Mike Romanos, Chief Scientific Officer of Crescendo, to drive the development of the Company and its proprietary antibody fragment technologies following the recent £4.5 million seed round fundraising. Read more
Crescendo Biologics Raises £4.5 million in Seed-Funding
Led by Sofinnova Partners
12 October 2009
Crescendo Biologics (“Crescendo”) today announces it has raised £4.5 million in a seed-funding round to advance the development of its fragment antibody technology platforms. The funding round was led by Sofinnova Partners, a Paris-based venture capital firm, with Aitua, Avlar BioVentures and the Rainbow Seed Fund also participating. Read more
Mike Romanos Appointed as CSO of Crescendo Biologics
12 October 2009
Mike Romanos has been appointed Chief Scientific Officer of Crescendo Biologics (“Crescendo”) and joins the Board as a Director. Dr Romanos will take leadership of the company and its proprietary antibody fragment technologies following a £4.5 million seed fundraising round led by Sofinnova Partners. Read more